^
Association details:
Biomarker:KRAS G12C
Cancer:Solid Tumor
Drug:garsorasib (D-1553) (KRAS G12C inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Study to Evaluate D-1553 in Subjects With Solid Tumors

Excerpt:
...- Subject has KRasG12C mutation in tumor tissue or other biospecimens containing cancer cells or DNA....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors

Excerpt:
...Recommended phase II dose (RP2D) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation`Objective Response Rate (ORR) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutation...
Trial ID:
More C2 evidence
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Study to Evaluate D-1553 in Subjects With Lung Cancer

Excerpt:
...- Subject has KRasG12C mutation in tumor tissue or other biospecimens containing cancer cells or DNA....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer

Excerpt:
...- Subject has KRasG12C mutation in tumor tissue or other biospecimens containing cancer cells or DNA....
Trial ID:
Less C2 evidence
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

D-1553: A novel KRASG12C inhibitor with potent and selective cellular and in vivo antitumor activity

Published date:
05/09/2023
Excerpt:
The combination of D-1553 with chemotherapy, MEK inhibitor, or SHP2 inhibitor showed stronger potency on tumor growth inhibition or regression compared to D-1553 alone. These findings support the clinical evaluation of D-1553 as an efficacious drug candidate, both as a single agent or in combination, for patients with solid tumors harboring KRASG12C mutation.
Secondary therapy:
; ; Chemotherapy
DOI:
10.1111/cas.15829
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

932 - Discovery of D-1553, a novel and selective KRas-G12C Inhibitor with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models

Published date:
03/10/2021
Excerpt:
The anti-tumor activity of D-1553 is evaluated across a panel of cancer cell lines including lung, pancreatic and colorectal cancers and shown to be active only in cancer cells with KRas-G12C mutation....When D-1553 is combined with MEK inhibitor, SHP2 inhibitor or cytotoxic agents, further tumor growth inhibition or regression was observed in tumor xenograft models. These data suggest that D-1553 has anti-tumor activity in a broad spectrum of cancers and is suitable for tissue-agnostic clinical development targeting cancers with KRas-G12C mutation.
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

1056 - Potent in vivo anti-tumor activity of D-1553 as a single agent and in combination with targeted therapeutics in a broad spectrum of patient-derived xenograft tumor models with KRas G12C mutation

Published date:
03/10/2021
Excerpt:
In the lung cancer PDX models, D-1553 exhibited tumor growth inhibition (TGI) from 43.6% to 124.3%, with 4 out of 8 models showing tumor regression. In the colorectal cancer PDX models, the range of TGI was from 60.9% to 105.7%, with 3 out of 9 models showing regression. Combination treatment of D-1553 with chemotherapy and targeted agents demonstrated enhanced anti-tumor activity resulting in more tumor regression compared to single agent treatment.
Secondary therapy:
Chemotherapy